WYETH JAPAN OBTAINS APPROVAL FOR ANTI-AML AGENT MYLOTARG

Wyeth Japan announced on July 25 that it has obtained approval for Mylotarg, a proprietary preparation of gemtuzumab ozogamicin, from the Ministry of Health, Labor and Welfare. Mylotarg is a calicheamicin-conjugated humanized anti-CD33 monoclonal antibody indicated for the treatment of acute myeloid leukemia (AML). AML is the most frequent leukemia in adults.

Japan Corporate News Network (http://www.japancorp.net/Article.Asp?Art_ID=10567)